Dong Lihua, Lyu Juan, Ding Lili, Liu Zhongmin
Department of Critical Care Medicine, the First Hospital of Jilin University, Changchun 130021, Jilin, China. Corresponding author: Liu Zhongmin, Email:
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2017 Feb;29(2):184-187. doi: 10.3760/cma.j.issn.2095-4352.2017.02.019.
Sepsis is a life-threatening organ dysfunction caused by dysregulated host responses to infection. Despite decades of research, it remains the leading cause of death in intensive care units (ICUs). None of the current treatment, including antibiotics, organ protection and liquid resuscitation, is specifically effective for sepsis. Immunosuppression is one of the currently accepted pathogenesis and immunotherapy is one of the hot spot of current sepsis research. Immune related treatments include restricting the release of pathogen toxin and its removal, controlling the excessive inflammatory reaction and apoptosis inhibition, etc. Numerous pre-clinical studies using immunomodulatory agents such as interleukin-7 (IL-7), anti-programmed cell death-1 (PD-1) antibody and others, have demonstrated reversal of T cell dysfunction and improved survival resulting from reviewing recent advances in immunotherapy of sepsis. Therefore, immunotherapy may be a new way of sepsis treatment.
脓毒症是由宿主对感染的反应失调引起的危及生命的器官功能障碍。尽管经过数十年的研究,它仍然是重症监护病房(ICU)死亡的主要原因。目前包括抗生素、器官保护和液体复苏在内的任何治疗方法对脓毒症都没有特效。免疫抑制是目前公认的发病机制之一,免疫治疗是当前脓毒症研究的热点之一。免疫相关治疗包括限制病原体毒素的释放及其清除、控制过度的炎症反应和抑制细胞凋亡等。许多使用白细胞介素-7(IL-7)、抗程序性细胞死亡蛋白1(PD-1)抗体等免疫调节剂的临床前研究,通过回顾脓毒症免疫治疗的最新进展,已证明T细胞功能障碍得到逆转且生存率提高。因此,免疫治疗可能是脓毒症治疗的新途径。